Status:
UNKNOWN
Hemodynamic Effect of Dexmedetomidine Alone With Dexmedetomidine Plus Ketamine Combination in CABG
Lead Sponsor:
Chaudhry Pervaiz Elahi Institute of Cardiology
Conditions:
Hemodynamic Instability
Eligibility:
All Genders
20-60 years
Phase:
NA
Brief Summary
In post cardiac surgery, many cardiovascular and other complications may occur that lead to increase in mortality and hospital stays. Meticulous perioperative management is important to avoid these ad...
Detailed Description
Dexmedetomidine is a highly specific alpha 2 adrenoreceptor agonist. Its sedative effect results from stimulation of alpha 2 adrenoreceptors in the central nervous system (in the locus coeruleus) inde...
Eligibility Criteria
Inclusion
- Patients of 40-60 years old Hemodynamically stable with normal or moderately impaired left ventricular function Ejection fraction \>40% that underwent elective surgery CABG surgery for single vessel
Exclusion
- Hemodynamic instability intraoperative. Patients on moderate to high vasopressors or ionotropes. Ejection fraction less than 40%. Off pump surgery. Patient on mechanical supports.
Key Trial Info
Start Date :
January 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2022
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05218161
Start Date
January 1 2021
End Date
March 1 2022
Last Update
February 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CPEIC
Multan, Pakistan